Table 2.
Treatment | ||
Protein (pg/ml) | PBS | 100 μg Poly(I:C) |
IFNγ | 11.0 +/- 1.6 | 52.2 +/- 11.2 ** |
IL-1α | 16.5 +/- 1.2 | 21.8 +/- 1.4 * |
IL-6 | 8.8 +/- 1.5 | 879.0 +/- 171.2 ** |
CXCL10 | 30.3 +/- 5.9 | 411.3 +/- 34.9 ** |
JE | 11.7 +/- 1.2 | 798.7 +/- 182.6 ** |
KC | 6.2 +/- 1.3 | 55.4 +/- 6.5 ** |
GCSF | 5.2 +/- 0.7 | 60.6 +/- 6.8 ** |
MIP1α | 37.7 +/- 6.3 | 441.1 +/- 61.6 ** |
RANTES | 0.5 +/- 0.04 | 155.8 +/- 41.6 ** |
TNFα | 2.3 +/- 0.33 | 81.2 +/- 13.7 ** |
GMCSF | 19.1 +/- 2.1 | 33.5 +/- 4.5 * |
Mice were administered PBS or 100 μg polyI:C (I.N.) every 24 h for three days. 24 h following the last polyI:C administration, BALs were performed. Analyte levels in BAL were determined. Data are expressed as mean pg/ml ± SEM from 6 – 8 mice. Statistical significance was determined using the Mann-Whitney test. * p < 0.05, **p < 0.01 when compared to PBS-treated mice. There was no measureable change in the following cytokines (data not shown): IL-1β, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12(p70), IL-9, IL-13, IL-15, or IL-17.